Protein phosphatase 2 explained

protein phosphatase 2, catalytic subunit, alpha isoform
Caption:The catalytic (C) subunit of protein phosphatase 2A. The protein is shown in rainbow color with the N-terminus in blue and the C-terminus in red. The methylated carboxyl group of the C-terminal leucine residue is shown in white. The purple spheres are two catalytically required manganese ions and the dark gray compound at center is a peptidomimetic toxin, microcystin, occupying the active site. From .[1]
Hgncid:9299
Symbol:PPP2CA
Entrezgene:5515
Omim:176915
Refseq:NM_002715
Uniprot:P67775
Ecnumber:3.1.3.16
Chromosome:5
Arm:q
Band:23
Locussupplementarydata:-q31
protein phosphatase 2, catalytic subunit, beta isoform
Hgncid:9300
Symbol:PPP2CB
Entrezgene:5516
Omim:176916
Refseq:NM_001009552
Uniprot:P62714
Ecnumber:3.1.3.16
Chromosome:8
Arm:p
Band:12

Protein phosphatase 2 (PP2), also known as PP2A, is an enzyme that in humans is encoded by the PPP2CA gene.[2] [3] The PP2A heterotrimeric protein phosphatase is ubiquitously expressed, accounting for a large fraction of phosphatase activity in eukaryotic cells.[4] Its serine/threonine phosphatase activity has a broad substrate specificity and diverse cellular functions. Among the targets of PP2A are proteins of oncogenic signaling cascades, such as Raf, MEK, and AKT, where PP2A may act as a tumor suppressor.

Structure and function

PP2A consists of a dimeric core enzyme composed of the structural A and catalytic C subunits, and a regulatory B subunit. When the PP2A catalytic C subunit associates with the A and B subunits several species of holoenzymes are produced with distinct functions and characteristics. The A subunit, a founding member of the HEAT repeat protein family (huntingtin, EF3, PP2A, TOR1), is the scaffold required for the formation of the heterotrimeric complex. When the A subunit binds it alters the enzymatic activity of the catalytic subunit, even if the B subunit is absent. While C and A subunit sequences show remarkable sequence conservation throughout eukaryotes, regulatory B subunits are more heterogeneous and are believed to play key roles in controlling the localization and specific activity of different holoenzymes. Multicellular eukaryotes express four classes of variable regulatory subunits: B (PR55), B′ (B56 or PR61), B″ (PR72), and B‴ (PR93/PR110), with at least 16 members in these subfamilies. In addition, accessory proteins and post-translational modifications (such as methylation) control PP2A subunit associations and activities.

The two catalytic metal ions located in PP2A's active site are manganese.

Function Protein Description Note
Structural subunit A PP2A 65 kDa regulatory subunit A alpha isoform subunit A, PR65-alpha isoform
PP2A 65 kDa regulatory subunit A beta isoform subunit A, PR65-beta isoform
Regulatory subunit B PP2A 55 kDa regulatory subunit B alpha isoform subunit A, B-alpha isoform
PP2A 55 kDa regulatory subunit B beta isoform subunit B, B-beta isoform
PP2A 55 kDa regulatory subunit B gamma isoform subunit B, B-gamma isoform
PP2A 55 kDa regulatory subunit B delta isoform subunit B, B-delta isoform
PP2A 72/130 kDa regulatory subunit B subunit B, B''-PR72/PR130
PP2A 48 kDa regulatory subunit B subunit B, PR48 isoform
PP2A regulatory subunit B'' subunit gamma subunit G5PR
PP2A regulatory subunit B' subunit B', PR53 isoform
PP2A 56 kDa regulatory subunit alpha isoform subunit B, B' alpha isoform
PP2A 56 kDa regulatory subunit beta isoform subunit B, B' beta isoform
PP2A 56 kDa regulatory subunit gamma isoform subunit B, B' gamma isoform
PP2A 56 kDa regulatory subunit delta isoform subunit B, B' delta isoform
PP2A 56 kDa regulatory subunit epsilon isoform subunit B, B' epsilon isoform
Catalytic subunit C catalytic subunit alpha isoform
catalytic subunit beta isoform

Drug discovery

PP2 has been identified as a potential biological target to discover drugs to treat Parkinson's disease and Alzheimer's disease, however as of 2014 it was unclear which isoforms would be most beneficial to target, and also whether activation or inhibition would be most therapeutic.[5] [6]

PP2 has also been identified as a tumor suppressor for blood cancers, and as of 2015 programs were underway to identify compounds that could either directly activate it, or that could inhibit other proteins that suppress its activity.[7]

Further reading

External links

Notes and References

  1. Cho US, Xu W . Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme . Nature . 445 . 7123 . 53–7 . January 2007 . 17086192 . 10.1038/nature05351 . 2007Natur.445...53C . 4408160 .
  2. Jones TA, Barker HM, da Cruz e Silva EF, Mayer-Jaekel RE, Hemmings BA, Spurr NK, Sheer D, Cohen PT . Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23→q31 and 8p12→p11.2, respectively . Cytogenetics and Cell Genetics . 63 . 1 . 35–41 . 1993 . 8383590 . 10.1159/000133497 .
  3. Virshup. David M.. Shenolikar. Shirish. 2009. From Promiscuity to Precision: Protein Phosphatases Get a Makeover. Molecular Cell. en. 33. 5. 537–545. 10.1016/j.molcel.2009.02.015. 19285938. free.
  4. Mumby M . PP2A: unveiling a reluctant tumor suppressor . . 130 . 1 . 21–24 . 2007 . 10.1016/j.cell.2007.06.034 . 17632053 . 16004039 . free .
  5. Braithwaite SP, Voronkov M, Stock JB, Mouradian MM . Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease . Neurochemistry International . 61 . 6 . 899–906 . November 2012 . 22342821 . 10.1016/j.neuint.2012.01.031 . 30417962 .
  6. Sontag JM, Sontag E . Protein phosphatase 2A dysfunction in Alzheimer's disease . Frontiers in Molecular Neuroscience . 7 . 16 . 2014 . 24653673 . 3949405 . 10.3389/fnmol.2014.00016 . free .
  7. Ciccone M, Calin GA, Perrotti D . From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies . Frontiers in Oncology . 5 . 21 . 2015 . 25763353 . 4329809 . 10.3389/fonc.2015.00021 . free .